Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

被引：85
|
作者：
Yu, Fei [1 ]
Xiang, Rong [1 ]
Deng, Xiaoqian [1 ]
Wang, Lili [2 ]
Yu, Zhengsen [1 ]
Tian, Shijun [1 ]
Liang, Ruiying [1 ]
Li, Yanbai [1 ]
Ying, Tianlei [3 ]
Jiang, Shibo [3 ]
机构：
[1] Hebei Agr Univ, Coll Life Sci, Baoding, Peoples R China
[2] Hebei Agr Univ, Res Ctr Chinese Jujube, Baoding, Peoples R China
[3] Fudan Univ, Sch Basic Med Sci, CAMS, Key Lab Med Mol Virol,MOE,NHC, Shanghai, Peoples R China
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2020年 / 5卷 / 01期
基金：
中国国家自然科学基金;
关键词：
ACUTE RESPIRATORY SYNDROME; CORONAVIRUS SPIKE PROTEIN; POTENT NEUTRALIZATION; VIRUS; IMMUNOPROPHYLAXIS; IDENTIFICATION; GENERATION; EPITOPES; FRAGMENT; VACCINE;
D O I：
10.1038/s41392-020-00318-0
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.
引用
收藏
页数：12
相关论文
共 50 条
  • [1] Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
    Fei Yu
    Rong Xiang
    Xiaoqian Deng
    Lili Wang
    Zhengsen Yu
    Shijun Tian
    Ruiying Liang
    Yanbai Li
    Tianlei Ying
    Shibo Jiang
    Signal Transduction and Targeted Therapy, 5
  • [2] Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
    Jinkai Zang
    Chenjian Gu
    Bingjie Zhou
    Chao Zhang
    Yong Yang
    Shiqi Xu
    Lulu Bai
    Rong Zhang
    Qiang Deng
    Zhenghong Yuan
    Hong Tang
    Di Qu
    Dimitri Lavillette
    Youhua Xie
    Zhong Huang
    Cell Discovery, 6
  • [3] Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
    Zang, Jinkai
    Gu, Chenjian
    Zhou, Bingjie
    Zhang, Chao
    Yang, Yong
    Xu, Shiqi
    Bai, Lulu
    Zhang, Rong
    Deng, Qiang
    Yuan, Zhenghong
    Tang, Hong
    Qu, Di
    Lavillette, Dimitri
    Xie, Youhua
    Huang, Zhong
    CELL DISCOVERY, 2020, 6 (01)
  • [4] Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
    Yuan, Meng
    Liu, Hejun
    Wu, Nicholas C.
    Wilson, Ian A.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 538 : 192 - 203
  • [5] A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
    Niu, Ling
    Wittrock, Kathryn N.
    Clabaugh, Gage C.
    Srivastava, Vikram
    Cho, Michael W.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [6] Immunogenicity of SARS-CoV: The receptor-binding domain of S protein is a major target of neutralizing antibodies
    He, Yuxian
    NIDOVIRUSES: TOWARD CONTROL OF SARS AND OTHER NIDOVIRUS DISEASES, 2006, 581 : 539 - 542
  • [7] Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice
    Zhang, Qiong
    Tiwari, Shashi
    Wen, Jing
    Wang, Shaobo
    Wang, Lingling
    Li, Wanyu
    Zhang, Lingzhi
    Rawling, Stephen
    Cheng, Yong
    Jokerst, Jesse
    Rana, Tariq M.
    PLOS ONE, 2024, 19 (04):
  • [8] Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain
    Huang, Ping-Han
    Tsai, Hsiao-Han
    Liao, Bo-Hung
    Lin, Yi-Ling
    Jan, Jia-Tsrong
    Tao, Mi-Hua
    Chou, Yu-Chi
    Hu, Che-Ming Jack
    Chen, Hui-Wen
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 654 - 655
  • [9] SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
    Law, John Lok Man
    Logan, Michael
    Joyce, Michael A.
    Landi, Abdolamir
    Hockman, Darren
    Crawford, Kevin
    Johnson, Janelle
    LaChance, Gerald
    Saffran, Holly A.
    Shields, Justin
    Hobart, Eve
    Brassard, Raelynn
    Arutyunova, Elena
    Pabbaraju, Kanti
    Croxen, Matthew
    Tipples, Graham
    Lemieux, M. Joanne
    Tyrrell, D. Lorne
    Houghton, Michael
    VACCINE, 2021, 39 (40) : 5769 - 5779
  • [10] On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2
    Giron, Carolina Correa
    Laaksonen, Aatto
    Barroso da Silva, Fernando L.
    VIRUS RESEARCH, 2020, 285
12345